Tralokinumab-ldrm - Biologic Drug Details

Summary for tralokinumab-ldrm

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for tralokinumab-ldrm

Mechanism of Action	Interleukin-13 Antagonists
Established Pharmacologic Class	Interleukin-13 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tralokinumab-ldrm Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tralokinumab-ldrm Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tralokinumab-ldrm Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Tralokinumab-ldrm

Last updated: February 20, 2026

What is Tralokinumab-ldrm?

Tralokinumab-ldrm (Brand: Adbry) is a biologic monoclonal antibody developed by Lilly targeting interleukin-13 (IL-13). It is approved for moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Market Landscape

Current Market Position

• Approval Status: U.S. approval by the FDA in December 2021; EMA approval in April 2022.
• Indications: Atopic dermatitis (atopic eczema) in adults.
• Competitors: Dupilumab (Dupixent), approved in 2017, dominates the atopic dermatitis biologic market. Other entrants include upadacitinib and tralokinumab's potential competitors such as Nemolizumab.

Market Size and Growth

• Global Atopic Dermatitis Market: Valued at approximately $8.3 billion in 2022; projected compound annual growth rate (CAGR) of 8% through 2030.
• Biologic Segment: Represents 60-70% of the total market, driven by biologics' efficacy in moderate-to-severe cases.

Adoption Trends

• Initial uptake is slow, constrained by existing treatment efficacy, physicians' familiarity, and insurance coverage.
• Early clinical data show that tralokinumab is effective but less rapid in symptom relief compared to dupilumab.
• Reimbursement pathways and formulary inclusion are critical to expanding access.

Competitive Positioning

Attribute	Tralokinumab-ldrm (Adbry)	Dupilumab (Dupixent)	Upadacitinib (Rinvoq)
FDA approval date	December 2021	March 2017	August 2019
Mechanism of action	IL-13 inhibition	IL-4/IL-13 inhibition	JAK inhibition
Administration	Subcutaneous injection (once weekly or biweekly)	Subcutaneous injection (biweekly)	Oral daily
Pricing (2023)	Approx. $6,500 per dose	Approx. $6,000 per dose	Approx. $45,000 per year (oral regimen)
Efficacy	Significant improvement in EASI score	Higher efficacy, faster onset	Moderate to high efficacy

Unique Selling Proposition

Tralokinumab's specificity for IL-13 offers a targeted approach with potentially fewer side effects and fewer off-target effects than broader immunomodulators like JAK inhibitors. Its less aggressive immune modulation appeals to certain patient populations.

Revenue Trajectory

Near-Term Outlook (2023-2025)

• Sales Estimates: Lilly forecasted $400-600 million in revenues for tralokinumab in 2023. Actual sales are around $250 million, with growth expected as formulary coverage expands.
• Market Penetration: Adoption remains limited in the U.S., limited by existing biologics' dominance and slower dosing ease.

Mid-to-Long Term Outlook (2026-2030)

• Growth Drivers: Increased diagnosis, expanded insurance coverage, new indications (e.g., pediatric atopic dermatitis), and combination therapies.
• Forecasted Revenue: Analysts project revenue reaching $1.2 billion by 2028, assuming steady market share gains.

Risks to Financial Trajectory

• Competition from more efficacious or convenient treatments.
• Delays in approval for additional indications.
• Pricing pressures as biosimilar versions or generics emerge.

Regulatory and Commercial Milestones

Date	Milestone	Impact
Dec 2021	FDA approval	Entry into the U.S. market
Apr 2022	EMA approval	Entry into European markets
2023	Initiations of pediatric trials	Potential expansion into pediatric atopic dermatitis
2024-2025	Potential label expansion	Broadened indication eligibility, revenue boost

Policy and Market Challenges

• Pricing and Reimbursement: High drug costs face scrutiny; payer negotiations are ongoing.
• Market Access: Competition from established biologics influences formulary inclusion.
• Innovation Pace: The development of oral or less invasive therapies may threaten the biologic segment.

Key Takeaways

• Tralokinumab-ldrm is a late entrant competing primarily with dupilumab.
• Current sales are limited but expected to grow as coverage widens.
• The biologic market for atopic dermatitis is expanding, driven by increased diagnosis and newer therapies.
• Revenue growth depends on market penetration, regulatory milestones, and competitive pressures.
• Payers' acceptance and drug pricing remain critical in shaping its long-term market share.

FAQs

1. What distinguishes tralokinumab from its competitors?
   It selectively inhibits IL-13, potentially offering fewer side effects than broader immunomodulators.

2. How quickly is tralokinumab being adopted clinically?
   Slow initial adoption due to existing preferred treatments and coverage issues, expected to improve with broader reimbursement.

3. What are the main barriers to its growth?
   Competition from dupilumab, pricing pressures, and the need for more extensive real-world efficacy data.

4. Will tralokinumab expand beyond adult atopic dermatitis?
   Lilly is testing pediatric indications; a broader label could significantly boost sales.

5. What are the prospects for biosimilar competition?
   Biosimilar versions are unlikely before 2030 due to patent protections and regulatory hurdles.

---

References

[1] EvaluatePharma. (2023). 2023 World Preview: Forecasts for Major Pharmaceutical Markets.
[2] IQVIA. (2022). Global Dermatology Market Analysis.
[3] U.S. Food and Drug Administration. (2021). FDA approves Adbry for atopic dermatitis.
[4] European Medicines Agency. (2022). EMA approval of Tralokinumab for adult atopic dermatitis.